Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.

Nature reviews. Clinical oncology·2026
Same author

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Deciphering small sequence differences in T cell receptor-antigen pairing.

Nature communications·2026
Same author

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with <i>ALK-</i>Positive Non-Small Cell Lung Cancer.

Cancer communications (London, England)·2026
Same author

Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Antibody-Drug Conjugates in Non-small Cell Lung Cancer.

Drugs·2026
Same journal

Accidental hypothermia.

Nature reviews. Disease primers·2026
Same journal

Accidental hypothermia.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Buruli ulcer in Africa: between innovation and pragmatism.

Nature reviews. Disease primers·2026
Same journal

Author Correction: Atopic dermatitis.

Nature reviews. Disease primers·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Non-small-cell lung cancer.

Lizza E L Hendriks1, Jordi Remon2, Corinne Faivre-Finn3

  • 1Department of Pulmonary Diseases, GROW-School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands.

Nature Reviews. Disease Primers
|September 26, 2024
PubMed
Summary
This summary is machine-generated.

Advances in non-small-cell lung cancer (NSCLC) management, including screening, surgical techniques, and targeted therapies, are improving patient outcomes. Personalized treatment strategies are key for future progress in NSCLC care.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Related Experiment Videos

Last Updated: Jun 12, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Area of Science:

  • Oncology
  • Pulmonology
  • Cancer Research

Background:

  • Non-small-cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
  • Recent advancements in the last decade have significantly improved NSCLC management and patient prognosis.
  • Key areas of improvement include screening, surgical and radiotherapeutic techniques, and systemic treatments.

Purpose of the Study:

  • To review the recent improvements in the management of non-small-cell lung cancer.
  • To highlight the impact of novel strategies on patient outcomes in both non-metastatic and metastatic NSCLC.
  • To emphasize the future direction of individualized treatment concepts.

Main Methods:

  • Review of recent literature and clinical advancements in NSCLC management.
  • Analysis of the impact of systematic screening (low-dose CT) on early detection.
  • Evaluation of novel surgical, radiotherapeutic, and systemic treatment options.

Main Results:

  • Improved cure rates in non-metastatic NSCLC through perioperative strategies and adjuvant immunotherapy for locally advanced disease.
  • Prolonged disease control and preserved quality of life in metastatic NSCLC with novel drug implementation.
  • Significant progress in understanding NSCLC biology leading to innovative systemic therapies.

Conclusions:

  • The prognosis for NSCLC patients has improved due to advancements in screening, treatment modalities, and biological understanding.
  • Combination strategies and novel drugs offer enhanced outcomes for both early-stage and advanced NSCLC.
  • Development of predictive clinical and genetic markers is crucial for future personalized NSCLC treatment.